Document:

Amendment No.6 to the Credit Agreement Dated as of August 20, 2004

 Exhibit 10.1 
 EXECUTION COPY 
 AMENDMENT NO. 6 dated as of November 30, 2007 (this “Amendment”),
among US ONCOLOGY HOLDINGS, INC. (“Holdings”), US ONCOLOGY, INC. (the “Borrower”), the Subsidiary Loan Parties (as defined in the Credit Agreement (as defined below)), the Lenders party hereto and JPMORGAN
CHASE BANK, N.A., as Administrative Agent. 
 A. Pursuant to the Credit Agreement dated as of August 20, 2004, as amended as of
March 17, 2005, November 15, 2005, July 10, 2006, December 21, 2006 and March 1, 2007 (the “Credit Agreement”), among Holdings, the Borrower, the Lenders party thereto, JPMorgan Chase Bank, N.A., as
Administrative Agent and Collateral Agent, Wachovia Bank, National Association, as Syndication Agent, and Citicorp North America, Inc., as Documentation Agent, the Lenders and the Issuing Banks (such terms and each other capitalized term used but
not defined herein having the meaning assigned to each such term in the Credit Agreement (as amended hereby)) have extended credit to the Borrower, and have agreed to extend credit to the Borrower, in each case pursuant to the terms and subject to
the conditions set forth therein. 
 B. The Borrower has requested that the Lenders agree to amend certain provisions of the Credit Agreement
and the Guarantee and Collateral Agreement as set forth herein. 
 C. The undersigned Lenders are willing so to amend the Credit Agreement,
pursuant to the terms and subject to the conditions set forth herein. 
 Accordingly, in consideration of the mutual agreements herein
contained and other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, and subject to the conditions set forth herein, the parties hereto agree as follows: 
 SECTION 1. Defined Terms. As used in this Amendment, the following term has the meaning specified below: 
 “Amendment Fee” shall have the meaning set forth in Section 10 hereof. 
 SECTION 2. Amendments to Section 1.01. Section 1.01 of the Credit Agreement is hereby amended as follows: 
 (a) by inserting the following definitions in the appropriate alphabetical order: 
 “Amendment No. 6 Effective Date” shall mean the date on which Amendment No. 6 to this Agreement shall have
become effective following the due satisfaction of the conditions set forth or referred to in Section 9(a) thereof. 
  

 1 

 “Risk Retention Subsidiary” shall mean any Subsidiary established for
the sole purpose of retaining risks relating to the operations of the Borrower, the Subsidiaries and the Affiliated Practices (including members of such Affiliated Practices), provided that any Equity Interests of such Subsidiary that are not
owned by the Borrower are owned by Subsidiaries and Affiliated Practices (including members of such Affiliated Practices). 
 (b) the definition of the term “Consolidated EBITDA” in Section 1.01 of the Credit Agreement is hereby amended by (i) inserting “(and, other than with respect to the calculation of the Leverage Ratio for
purposes of the definition of Applicable Rate, Additional Physician Affiliation)” immediately after the text “Section 6.05” in the proviso to clause (b) thereof and (ii) by inserting “or Additional Physician
Affiliation” immediately after the second occurrence of the text “Material Disposition” in such proviso. 
 (c)
the definition of the term “Pro Forma Basis” in Section 1.01 of the Credit Agreement is hereby amended and restated in its entirety as follows: 
 “Pro Forma Basis” means, with respect to the calculation of a Financial Performance Covenant in connection with
(a) a Permitted Acquisition, (b) an Additional Physician Affiliation or (c) any issuance, incurrence or assumption of Indebtedness, that such calculation shall give pro forma effect to such Permitted Acquisition or Additional
Physician Affiliation, or issuance, incurrence or assumption of Indebtedness, and all other Permitted Acquisitions and Additional Physician Affiliations and issuances, incurrences or assumptions of debt and all Material Dispositions that have
occurred since the beginning of the four consecutive fiscal quarters period for which such calculation is being made as if it occurred on the first day of such four consecutive fiscal quarter period (including cost savings to the extent such cost
savings would be permitted to be reflected in pro forma financial information complying with the requirements of GAAP and Article XI of Regulation S-X under the Securities Act of 1933, as amended, as interpreted by the Staff of the SEC,
and as certified by a Financial Officer). 
 (d) the definition of the term “Subsidiary” in Section 1.01
of the Credit Agreement is hereby amended by (i) replacing “and” immediately following “Inactive Subsidiary” with “,” and (ii) inserting “and (d) Risk Retention Subsidiary” immediately following
“Insurance Subsidiary”. 
  

 2 

 (e) the definition of the term “Applicable Rate” in Section 1.01 of
the Credit Agreement is hereby amended by deleting the pricing tables contained therein in their entirety and inserting the following tables set forth below: 
  

										
	 Leverage Ratio:
	  	Revolving
Loan ABR
Spread	 	 	Revolving
Loan
Eurodollar
Spread	 	 	Commitment
Fee Rate	 
	 Category 1
Greater than 4.00 to 1.00
	  	1.75	%	 	2.75	%	 	0.50	%
	 Category 2
Equal to or less than 4.00 to 1.00 but greater than or equal to 3.75 to
1.00
	  	1.50	%	 	2.50	%	 	0.50	%
	 Category 3
Less than 3.75 to 1.00 but greater than 3.50 to 1.00
	  	1.50	%	 	2.50	%	 	0.50	%
	 Category 4
Less than or equal to 3.50 to 1.00 but greater than 3.25 to 1.00
	  	1.25	%	 	2.25	%	 	0.50	%
	 Category 5
Less than or equal to 3.25 to 1.00
	  	1.00	%	 	2.00	%	 	0.375	%

  

													
	 Leverage Ratio:
	  	Tranche B
Term Loan
ABR
Spread	 	 	Tranche B
Term Loan
Eurodollar
Spread	 	 	Tranche C
Term Loan
ABR
Spread	 	 	Tranche C
Term Loan
Eurodollar
Spread	 
	 Greater than or equal to 4.50 to 1.00
	  	1.75	%	 	2.75	%	 	1.75	%	 	2.75	%
	 Less than 4.50 to 1.00
	  	1.50	%	 	2.50	%	 	1.50	%	 	2.50	%

 SECTION 3. Amendment to Section 6.01. Section 6.01 of the Credit Agreement is
hereby amended as follows: 
 (a) clause (iii) is hereby amended by inserting the text “and Additional Physician
Notes issued prior to the Amendment No. 6 Effective Date” at the end thereof. 
 (b) clause (xviii) is hereby
amended by replacing “$25,000,000” with “$35,000,000”. 
  

 3 

 (c) clause (xxi) is hereby amended by replacing clause (A) thereof with the
following text: “(A) the aggregate principal amount of Additional Physician Notes issued pursuant to this clause (xxi) on or after the Amendment No. 6 Effective Date shall not exceed $140,000,000 (excluding any additional
principal amounts resulting from pay-in-kind interest), “. 
 SECTION 4. Amendment to Section 6.04. Section 6.04 of the
Credit Agreement is hereby amended as follows: 
 (a) clause (xvi) is hereby amended by replacing “$30,000,000”
with “$50,000,000”. 
 (b) clause (xvii) is hereby amended by (i) inserting the text “or guarantees
of obligations of Affiliated Practices” after the text “advances to Affiliated Practices”, (ii) deleting the text “and consistent with past practice” and (iii) replacing “$30,000,000” with
“$50,000,000”. 
 (c) clause (xviii) is hereby amended by inserting the text “or any Risk Retention
Subsidiary” after the text “any Insurance Subsidiary”. 
 (d) clause (xix) is hereby amended by
(a) replacing the text “Additional Physician Affiliations” at the beginning thereof with the text “(A) Additional Physician Affiliations consummated prior to the Amendment No. 6 Effective Date and (B) Additional
Physician Affiliations consummated after the Amendment No. 6 Effective Date” and (b) replacing “50,000,000” with “140,000,000”. 
 SECTION 5. Amendment to Section 6.12. Section 6.12 is hereby amended by deleting the chart set forth therein in its entirety and by inserting the following chart as set forth below: 
  

			
	 Period
	  	Ratio
	 December 31, 2004
	  	2.00 to 1.00
	 March 31, 2005
	  	2.00 to 1.00
	 June 30, 2005
	  	2.00 to 1.00
	 September 30, 2005
	  	2.00 to 1.00
	 December 31, 2005
	  	2.00 to 1.00
	 March 31, 2006
	  	2.00 to 1.00
	 June 30, 2006
	  	2.05 to 1.00
	 September 30, 2006
	  	2.10 to 1.00
	 December 31, 2006
	  	2.15 to 1.00
	 March 31, 2007
	  	2.15 to 1.00

  

 4 

			
	 June 30, 2007
	  	2.20 to 1.00
	 September 30, 2007
	  	2.25 to 1.00
	 December 31, 2007
	  	2.00 to 1.00
	 March 31, 2008
	  	1.90 to 1.00
	 June 30, 2008
	  	1.90 to 1.00
	 September 30, 2008
	  	1.95 to 1.00
	 December 31, 2008
	  	1.95 to 1.00
	 March 31, 2009
	  	2.00 to 1.00
	 June 30, 2009
	  	2.00 to 1.00
	 September 30, 2009
	  	2.15 to 1.00
	 December 31, 2009
	  	2.15 to 1.00
	 March 31, 2010
	  	2.30 to 1.00
	 June 30, 2010
	  	2.30 to 1.00
	 September 30, 2010
	  	2.30 to 1.00
	 December 31, 2010
	  	2.30 to 1.00
	 March 31, 2011
	  	2.50 to 1.00
	 June 30, 2011
	  	2.50 to 1.00
	 September 30, 2011
	  	2.50 to 1.00

 SECTION 6. Amendment to Section 6.13. Section 6.13 is hereby amended by deleting
the chart set forth therein in its entirety and by inserting the following chart as set forth below: 
  

			
	 Period
	  	Ratio
	 December 31, 2004
	  	5.95 to 1.00
	 March 31, 2005
	  	5.95 to 1.00
	 June 30, 2005
	  	5.95 to 1.00
	 September 30, 2005
	  	5.95 to 1.00
	 December 31, 2005
	  	5.95 to 1.00
	 March 31, 2006
	  	5.95 to 1.00
	 June 30, 2006
	  	5.75 to 1.00
	 September 30, 2006
	  	5.50 to 1.00
	 December 31, 2006
	  	5.25 to 1.00
	 March 31, 2007
	  	5.25 to 1.00
	 June 30, 2007
	  	5.00 to 1.00

  

 5 

			
	 September 30, 2007
	  	5.00 to 1.00
	 December 31, 2007
	  	5.75 to 1.00
	 March 31, 2008
	  	5.95 to 1.00
	 June 30, 2008
	  	5.95 to 1.00
	 September 30, 2008
	  	5.75 to 1.00
	 December 31, 2008
	  	5.60 to 1.00
	 March 31, 2009
	  	5.60 to 1.00
	 June 30, 2009
	  	5.40 to 1.00
	 September 30, 2009
	  	5.40 to 1.00
	 December 31, 2009
	  	5.25 to 1.00
	 March 31, 2010
	  	5.25 to 1.00
	 June 30, 2010
	  	5.10 to 1.00
	 September 30, 2010
	  	5.10 to 1.00
	 December 31, 2010
	  	4.90 to 1.00
	 March 31, 2011
	  	4.90 to 1.00
	 June 30, 2011
	  	4.75 to 1.00
	 September 30, 2011
	  	4.75 to 1.00

 SECTION 7. Amendment to Section 1.01 of the Guarantee and Collateral Agreement.
Section 1.01 of the Guarantee and Collateral Agreement is hereby amended as follows: 
 (a) by inserting the definition
of the following term in the appropriate alphabetical order: 
 “Treasury Services Agreement” shall mean any
agreement relating to treasury, depositary and cash management services or automated clearinghouse transfer of funds. 
 (b)
the definition of the term “Obligation” in Section 1.01 of the Guarantee and Collateral Agreement is hereby amended by inserting the text “or Treasury Services Agreement” immediately following each occurrence of the text
“Swap Agreement”. 
 SECTION 8. Representations and Warranties. Holdings and the Borrower represent and warrant to the
Administrative Agent and to each of the Lenders that: 
 (a) This Amendment has been duly authorized, executed and delivered
by Holdings and the Borrower and constitutes a legal, valid and 

  

 6 

 
binding obligation of Holdings and the Borrower, enforceable against Holdings and the Borrower in accordance with its terms, subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law. 
 (b) The representations and warranties of each Loan Party set forth in the Loan Documents are true and correct in all material respects
(except to the extent any such representation or warranty is qualified by “materially,” “Material Adverse Effect” or a similar term, in which case such representation and warranty shall be true and correct in all respects) on and
as of the date hereof with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties were true and correct
(or true and correct in all material respects, as the case may be) as of such earlier date). 
 (c) Immediately after giving
effect to this Amendment, no Default shall have occurred and be continuing. 
 SECTION 9. Conditions to Effectiveness; Amendment.
(a) This Amendment shall become effective when (i) the Administrative Agent shall have received counterparts of this Amendment that, when taken together, bear the signatures of Holdings, the Borrower and the Required Lenders, (ii) the
representations and warranties set forth in Section 8 hereof are true and correct (as set forth on an officer’s certificate delivered to the Administrative Agent) and (iii) all fees (including the Amendment Fee) and, to the extent
invoiced prior to the date hereof, expenses required to be paid or reimbursed by the Borrower under or in connection with this Amendment or the Credit Agreement shall have been paid or reimbursed, as applicable. 
 (b) This Amendment may not be amended nor may any provision hereof be waived except pursuant to a writing signed by Holdings, the
Borrower, the Administrative Agent and the requisite Lenders under Section 9.02 of the Credit Agreement. 
 SECTION 10. Amendment
Fee. In consideration of the agreements of the Lenders contained in this Amendment, the Borrower agrees to pay promptly to the Administrative Agent, for the account of each Lender that delivers an executed counterpart of this Amendment at or
prior to 3:00 p.m., New York time, on November 27, 2007, an amendment fee (the “Amendment Fee”) in an amount equal to 0.25% of the sum of such Lender’s Revolving Exposure, unused Revolving Commitment and outstanding
Tranche B Term Loans and Tranche C Term Loans as of such time and date; provided that such Amendment Fee shall not be payable unless and until this Amendment becomes effective as provided in Section 9(a) above and upon such effectiveness
such Amendment Fee shall be payable immediately. 
  

 7 

 SECTION 11. Credit Agreement. Except as expressly set forth herein, this Amendment shall not by
implication or otherwise limit, impair, constitute a waiver of, or otherwise affect the rights and remedies of the Lenders, the Agents, the Issuing Bank, Holdings, the Borrower or any other Loan Party under the Credit Agreement or any other Loan
Document, and shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document, all of which are ratified and affirmed in all respects
and shall continue in full force and effect. Nothing herein shall be deemed to entitle Holdings or the Borrower to any future consent to, or waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or
agreements contained in the Credit Agreement or any other Loan Document in similar or different circumstances. After the date this Amendment becomes effective, any reference to the Credit Agreement shall mean the Credit Agreement as modified hereby.
This Amendment shall constitute a “Loan Document” for all purposes of the Credit Agreement and the other Loan Documents. 
 SECTION
12. Applicable Law. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
 SECTION 13. Counterparts. This Amendment may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one agreement. Delivery of an executed
signature page to this Amendment by facsimile transmission shall be effective as delivery of a manually signed counterpart of this Amendment. 
 SECTION 14. Expenses. The Borrower agrees to reimburse the Administrative Agent, the Syndication Agent and the Documentation Agent for out-of-pocket expenses in connection with this Amendment, including the fees, charges and
disbursements of Cravath, Swaine & Moore LLP, counsel for the Administrative Agent. 
 SECTION 15. Headings. The
headings of this Amendment are for purposes of reference only and shall not limit or otherwise affect the meaning hereof. 
 SECTION 16.
Severability. Any provision of this Amendment held to be invalid, illegal or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting
the validity, legality and enforceability of the remaining provisions hereof; and the invalidity of a particular provision in a particular jurisdiction shall not invalidate such provision in any other 

  

 8 

 
jurisdiction. The parties shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions, the
economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions. 
 [REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK] 
  

 9 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 6 to be duly executed by their
respective authorized officers as of the day and year first written above. 
  

			
	US ONCOLOGY HOLDINGS, INC.,
		
	By	 	 
		 	Name:
		 	Title:

  

 10 

			
	US ONCOLOGY, INC.,
		
	By	 	 
		 	Name:
		 	Title:

  

 11 

			
		  	SIGNATURE PAGE TO AMENDMENT NO. 6 AMONG US ONCOLOGY HOLDINGS, INC., US ONCOLOGY, INC., THE LENDERS PARTY THERETO AND JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT.

  

			
	NAME OF INSTITUTION:
		
	by	 	 
		 	Name:
		 	Title:

  

 12Development and License Agreement

 Exhibit 10.23 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 

Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
 DEVELOPMENT AND LICENSE AGREEMENT 
 This Development and License Agreement (the “Agreement”), effective as of September 15, 2002 (the “Effective Date”), is entered into by and between RF Magic, Inc., a Delaware
corporation having a place of business at 10182 Telesis Court, 4th Floor, San Diego, California 92121-4777, U.S.A. (“RFM”) and
STMicroelectronics N.V., with its registered office at WTC Schiphol Airport, Schiphol Boulevard 265, 1118 BH Schiphol Airport, Amsterdam, the Netherlands, acting through its Swiss Branch located at 39, Chemin du Champ des Filles,
1228 Plan-les-Ouates, Geneva, Switzerland (“ST”). 
 Recitals 
 WHEREAS, ST is a global independent semiconductor company which designs, develops, manufactures and markets a broad range of integrated circuits and
discrete devices based on semiconductors used in a wide variety of microelectronic applications, including telecommunication systems, computer systems, consumer products, automotive products and industrial automation and control systems. 

WHEREAS, RFM is a fabless semiconductor company that designs, builds (or has built on its behalf), and sells complex, highly integrated
systems-on-a-chip radio frequency integrated circuits for consumer broadband and entertainment markets. 
 WHEREAS, ST desires to obtain from
RFM certain rights to manufacture and sell certain integrated circuits for satellite single tuners to customers of ST. 
 WHEREAS, RFM is
willing, subject to the terms and conditions set forth below, to design the foregoing integrated circuits and develop certain hardware and software to help bring such integrated circuits into production, and is willing to deliver and license a GDSII
design file for the same to ST solely for ST to manufacture and sell such integrated circuits to customers of ST. 
 NOW, THEREFORE, in
furtherance of the foregoing recitals and in consideration of the mutual covenants and obligations set forth in this Agreement, the parties agree as follows: 
 Articles 
  

	 	1.	DEFINITIONS. 

 1.1
“Affiliates” shall mean a corporation or other legal entity controlling, controlled by, or under common control, now or hereafter, directly or indirectly, with ST, provided that such entity shall be considered an Affiliate only for
the time during which such control exists. For purposes of this definition “control” shall mean ownership or control, either directly or indirectly, of greater than fifty percent (50%) of the voting rights of such entity. 

1.2 “Customers” means customers of ST. 
 1.3 “Development Plan” means the development plan for the Product as set forth in Exhibit A. 
 1.4 “Development Schedule” means the development schedule for the Product as set forth in Exhibit B. 
 1.5 “Evaluation Circuit Design” means the circuit board design developed by RFM pursuant to this Agreement for use in evaluating the functionality of Products. 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 1.6 “Evaluation Software” means the software developed by RFM pursuant to this
Agreement to evaluate the functionality of Products relative to the Specifications, in object code only. 
 1.7 “Exclusive
Period” has the meaning set forth in Exhibit D. 
 1.8 “First Commercial Production Date” means has the
meaning set forth in Exhibit D. 
 1.9 “IC Design” means the integrated circuit design developed by RFM pursuant to
this Agreement for a radio frequency integrated circuit [...***...]. 
 1.10 “IC Design File” means the
[...***...] database file containing the IC Design information necessary to manufacture the Mask Tooling Set. 
 1.11
“Intellectual Property Rights” means any and all (by whatever name or term known or designated) tangible and intangible and now known or hereafter existing (a) rights associated with works of authorship, including but not
limited to copyrights, moral rights and mask-works, (b) rights in and relating to the protection of trademarks, service marks, trade names and goodwill, (c) rights in and relating to the protection of trade secrets and confidential
information, (d) patents, designs, algorithms and other industrial property rights and rights associated therewith, (e) other intellectual and industrial property and proprietary rights (of every kind and nature however designated)
relating to intangible property that are analogous to any of the foregoing rights, whether arising by operation of law, contract, license or otherwise, and (f) registrations, applications, renewals, extensions, continuations, divisions or
reissues thereof now or hereafter in force throughout the world (including without limitation rights in any of the foregoing). 
 1.12
“Manufacturing Test Circuit Design” means the circuit board design developed by the RFM pursuant to this Agreement, in accordance with the Development Plan, to test the functionality of Product upon completion of the manufacturing
and assembly of the Product. 
 1.13 “Manufacturing Test Software” means the software developed by RFM pursuant to this
Agreement, and in accordance with the Development Plan, that is used to confirm functionality of the Products during final testing in the Product manufacturing process, in object code. 
 1.14 “Mask Tooling Set” means the collection of masks used to manufacture the layers of Products, or any portion of a Product.

 1.15 “Product” means a radio frequency integrated circuit Manufactured by ST (or on behalf of ST pursuant to
Section 4.1(B)) that conforms to the IC Design. 
 1.16 “Reference Design” means the system level circuit board design,
including [...***...], developed by ST pursuant to this Agreement to demonstrate the functionality of the Products. 
 1.17
“RFM Materials” means the Evaluation Circuit Designs, Evaluation Software, Specifications, IC Designs, IC Design Files, Manufacturing, Test Circuit Designs and Manufacturing Test Software. 
 1.18 “Satellite Single Tuner” means a device that enables the selection and frequency conversion of [...***...]. 
 1.19 “Specifications” means the specifications set forth in Exhibit C. 
 1.20 “ST Deliverables” means the demodulator software drivers needed to develop the Evaluation Software and Evaluation Circuit Design.

  

 - 2 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 1.21 “ST Existing RF Product” has the meaning set forth in Exhibit D.

  

	 	2.	SCOPE OF AGREEMENT. 

 Prior to any exercise of any rights (including, without limitation, license rights) by an Affiliate, ST shall (a) cause such Affiliate to agree to be bound by all the terms of this Agreement to the same extent as
ST is bound, and (b) provide RFM with notice of the name and legal address of each Affiliate to be included within the scope of this Agreement. ST unconditionally guarantees performance by each Affiliate of all of the obligations hereunder to
the same extent ST is bound to perform under this Agreement, without prejudice to RFM’s right to seek injunctive relief for breach of this Agreement directly against such Affiliate if RFM so elects. 
  

	 	3.	DEVELOPMENT. 

 3.1 In General.
In accordance with the Development Plan and Development Schedule, RFM shall use commercially reasonable efforts, at RFM’s cost and expense, to develop the: (a) IC Designs in accordance with Specifications; and (b) Evaluation Software,
Manufacturing Test Software, Manufacturing Test Circuit Design and Evaluation Circuit Designs. The parties shall use commercially reasonable efforts, with each party responsible for and bearing its own costs and expenses in connection therewith, to
jointly develop the Reference Design in accordance with the Development Plan and Development Schedule. ST shall use commercially reasonable efforts, at ST’s cost and expense, to develop the Mask Tooling Sets in accordance with the Development
Plan and Development Schedule. Any failure to conform to Development Plan and Development Schedule shall not be deemed to be a material breach of this Agreement upon which a party may exercise termination rights under Section 9.3, unless a
party fails to use commercially reasonable efforts to meet such plans and schedules. ST agrees that RFM’s ability to comply with the Development Plan and Development Schedule depends on RFM receiving reasonable cooperation and assistance from
ST in accordance with RFM’s requests therefore. 
 3.2 Project Managers. Each party shall designate in writing to the other party
a project manager (the “Project Manager(s)”) who shall serve as the primary source of communication with the other party with respect to the development activities under Section 3.1. The Project Managers shall have primary
responsibility for coordinating all major decisions related to such development. Each party may replace its Project Manager from time to time, as it deems necessary or appropriate, upon written notice to the other party. 
 3.3 Testing and Acceptance. Within [...***...] after RFM’s delivery of the IC Design File to ST, ST shall manufacture and deliver a
commercially reasonable quantity of evaluation Product to RFM for evaluation testing. Upon RFM’s receipt of such Products from ST, RFM shall test such Products with the applicable Evaluation Software and in the applicable Evaluation Circuit
Design to determine if the IC Design for such Products conforms to the applicable Specifications. Upon completion of such testing, RFM shall provide ST with the data from such testing (“Evaluation Data”). Upon ST’s receipt of
the Evaluation Data, ST shall evaluate whether the Evaluation Data indicates that the IC Design conforms to the Specifications in all material respects. ST shall accept or reject the IC Design based on the Evaluation Data and shall give RFM written
notice thereof within seven (7) calendar days after RFM’s delivery of the Evaluation Data to ST. An IC Design will be deemed accepted by ST if RFM has not received notification of rejection of such IC Design from ST within seven
(7) calendar days after RFM’s delivery of the applicable Evaluation Data to ST. ST’s refusal to accept the IC Design must be reasonable, must be in writing and must be accompanied by a reasonably detailed description of the manner in
which the IC Design fails to comply with the Specifications in all material respects (collectively, the “Deficiencies”) so that RFM can have the opportunity to correct the Deficiencies. If ST properly rejects the IC Design, RFM
shall use commercially reasonable efforts to correct any Deficiencies and redeliver a corrected IC Design File within [...***...] after RFM’s receipt of the rejection notice and the foregoing provisions set forth in this Section 3.3
shall be reapplied until the IC Design is accepted; provided, however, that upon the [...***...] or any subsequent rejection, either party may terminate this Agreement upon thirty (30) calendar days prior written notice to the other
party, unless the IC Design is accepted during such notice period. 
  

 - 3 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

	 	4.	LICENSES. 

 4.1 Licenses.

 (A) Evaluation. Subject to the terms and conditions of this Agreement, RFM grants to ST and its Affiliates (subject to Article 2
above) a nontransferable (subject to Section 14.3), nonsublicenseable, nonexclusive license, under RFM’s Intellectual Property Rights in and to the Evaluation Software, Specifications and Evaluation Circuit Designs, to: (i) use and
reproduce the Evaluation Software and Specifications solely to conduct evaluation testing of the Products pursuant to Section 3.3; and (ii) use the Evaluation Circuit Designs solely to conduct evaluation testing of the Products pursuant to
Section 3.3. 
 (B) Manufacturing. Subject to the terms and conditions of this Agreement, RFM grants to ST and its Affiliates
(subject to Article 2 above) a nontransferable (subject to Section 14.3), nonsublicenseable, nonexclusive license, under RFM’s Intellectual Property Rights in and to the IC Designs, IC Design Files, Mask Tooling Sets, Manufacturing Test
Circuit Designs and Manufacturing Test Software, to: (i) make and have made the Products solely for sale to Customers pursuant to this Agreement (ii) use and reproduce the IC Design Files to manufacture and have manufactured the Mask
Tooling Sets solely for use in accordance with this Agreement; (iii) use the Mask Tooling Sets to manufacture and have manufactured Products solely for sale, either on a standalone basis or bundled with other ST semiconductor products, to
Customers solely in accordance with this Agreement, (iv) use the Manufacturing Test Circuit Designs solely to test the functionality of Products manufactured in accordance with this Agreement, and (v) use and reproduce the Manufacturing
Test Software solely to test the functionality of Products manufactured in accordance with this Agreement. 
 (C) Sales by ST.
Subject to the terms and conditions of this Agreement, RFM grants to ST and its Affiliates (subject to Article 2 above) a nontransferable (subject to Section 14.3), nonsublicenseable, nonexclusive license, under RFM’s Intellectual Property
Rights in and to IC Design and IC Design File, to offer for sale, sell, and import Products, either on a standalone basis or bundled with other ST semiconductor products, solely in accordance with this Agreement. 
 4.2 Exclusivity and Sales Requirements. 
 (A) During the Exclusive Period, RFM shall not (i) sell Products, or (ii) authorize any third party to sell and/or distribute Products. 
 (B) For the purposes of clarification, upon the expiration or termination of the Exclusive Period, RFM may sell or appoint third parties to sell radio frequency integrated circuits that conform to the Specifications;
and/or (b) buy Products from ST under the Supply Terms (as defined below). During the [...***...] period immediately following the Effective Date, the parties shall negotiate in good faith the certain supply terms for ST’s supply of
Product to RFM (“Supply Terms”) including, without limitation, the following terms: pricing, process qualification, order acceptance, lead times, order rescheduling, order cancellation, delivery, late deliveries, allocation, Product
acceptance, ST warranties, ST support, process changes and process discontinuance. 
 4.3 ST License Restrictions. ST shall not
itself, or through any Affiliate, agent, or third party: (a) sell, lease, license, sublicense or in any way have third parties use the RFM Materials; (b) decompile, disassemble, reverse engineer, or attempt to derive source code, as
applicable, from the RFM Materials, in whole or in part, except to the extent such restriction is prohibited by applicable law and not waiveable thereunder; (c) modify or create derivative works from the RFM Materials; or (d) use the RFM
Materials to provide processing services to third parties or otherwise use the RFM Materials on a service bureau basis. Except as expressly granted in this Agreement, RFM grants no license, by implication, estoppel, or otherwise to the RFM
Materials. 
 4.4 Subject to the terms and conditions of this Agreement, ST grants to RFM a non-exclusive, revocable (only upon expiration or
termination of the Agreement), non-transferable, limited, license, 

  

 - 4 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 
without the right to sublicense, to solely and only use ST Deliverables to develop the Evaluation Software and Evaluation Circuit Design and provide warranty
and other support for the Products. RFM may terminate the foregoing license upon written notice to ST. RFM may not transfer the foregoing license without ST’s prior written consent, such consent not to be unreasonably withheld or delayed.
RFM’s (an any Acquirer’s) nonperformance of its obligations to develop and deliver the Evaluation Software and Evaluation Circuit Design and to provide warranty and other support for the Products under this Agreement shall be excused if
and to the extent such RFM (or Acquirer’s) nonperformance relates to ST’s refusal to transfer the foregoing license upon request. ST shall deliver or has already delivered the ST Deliverables to RFM. 
 4.5 Except as necessary to exercise the license rights granted in Section 4.4, RFM shall not itself, or through any agent, or third party;
(a) sell, lease, license, sublicense or in any way have third parties use the ST Deliverables; (b) decompile, disassemble, reverse engineer, or attempt to derive source code, as applicable, from the ST Deliverables, in whole or in part,
except to the extent such restriction is prohibited by applicable law and not waiveable thereunder; (c) modify or create derivative works from the ST Deliverables; or (d) use the ST Deliverables to provide processing services to third
parties or otherwise use the ST Deliverables on a service bureau basis. Except as expressly granted in Section 4.4 above, ST grants to RFM no license, by implication, estoppel, or otherwise to the ST Deliverables. 
  

	 	5.	SALES ACTIVITIES AND CUSTOMER SUPPORT. 

 5.1 Conflict of Interest. During the Exclusive Period, ST shall not, without RFM’s prior written consent, develop, represent, promote or
otherwise try to sell, license or otherwise distribute, whether directly or indirectly, any products or services that in the parties’ reasonable judgment compete with the Products, except for the ST Existing RF Product. 
 5.2 Product Support. ST shall have the responsibility for supporting all Products distributed under this Agreement. ST shall ensure that all
Customer questions regarding the use or operation of Products are initially addressed to and answered by ST. Unless otherwise agreed in writing by RFM, ST shall not represent to any third party that RFM is available to answer questions received
directly from any Customer. Without limiting the foregoing, ST also shall be responsible for (x) providing sufficient information to RFM for RFM to duplicate any reported error related to the design in the Products; and (y) providing
reasonably cooperation and full information between the parties in the furnishing of support for the Products. 
  

	 	6.	MASK TOOLING SET. 

 6.1 Manufacture. ST shall manufacture, at its own expense, the Mask Tooling Sets. 
 6.2 Mask
Proprietary Rights. Except for the license granted under Section 4.1(B), RFM shall own all Intellectual Property Rights in and to the Mask Tooling Sets. Subject to the foregoing, ST shall own title to the tangible Mask Tooling Sets,
provided that such Mask Tooling Sets shall be used solely for the benefit of RFM in accordance with this Agreement. The Mask Tooling Set shall be treated as RFM’s Confidential Information in accordance with Article 12. ST agrees that the Mask
Tooling Set will at all times contain RFM’s trademark, mask work, and copyright notices. Upon expiration or termination of this Agreement (subject only to any ST right to fulfill purchase orders pursuant to Section 9.4(B), and in such
case, upon expiration of such rights), ST shall destroy the Mask Tooling Sets and certify in writing (by an authorized officer of ST) that the Mask Tooling Sets have been destroyed pursuant to this Section 6.2. 
  

	 	7.	PROPRIETARY RIGHTS. 

 7.1 RFM. Except for the licenses expressly granted by RFM to ST pursuant to Article 4, RFM and/or its licensors shall own all right, title and interest in and to the Evaluation Circuit Design, Evaluation Software, Manufacturing Test
Software, Specifications, IC Design, IC Design File and Manufacturing Test Circuit Design (“RFM Owned Materials”), including any Intellectual Property Rights therein. RFM and/or its licensors 

  

 - 5 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 
shall own all Intellectual Property Rights in and to the Mask Tooling Sets. Provided, however, that RFM’s ownership of the Evaluation Software shall not
be deemed to give RFM any ownership in any ST Deliverables including the Intellectual Property Rights therein, even though such ST Deliverables may be used with the Evaluation Software or the Evaluation Circuit Design. 
 7.2 ST. Subject to Section 7.1, ST shall own all of right, title and interest in and to the Reference Design, including any Intellectual
Property Rights therein. 
 7.3 Proprietary Notice. Each party shall reproduce and shall not remove, alter, cover or obfuscate any all
patent, copyright, trademark, and other proprietary notices contained in or on the RFM Materials, ST Deliverables or other materials that are provided by a party to the other. 
  

	 	8.	ROYALTIES AND PAYMENT. 

 8.1 Royalties. In consideration for the licenses granted by RFM to ST pursuant to this Agreement, ST shall pay RFM the royalty fees (“Royalties”) set forth in Exhibit D. 
 8.2 Reporting. Within [...***...] after the end of each calendar quarter, ST shall provide to RFM a written report that will contain at
minimum the total number of Products sold, the total number of Products for which royalty payment shall be made, the amounts invoiced for such Products; and the dates such Products were sold by ST and the Affiliates during such quarter. 

8.3 Payment. Within [...***...] after the end of each calendar quarter, ST shall pay RFM all Royalties due for such quarter. ST shall pay
all Royalties in full even if ST has not received payment from its Customers. All references to “dollars,” “U.S. $” or “$” shall mean United States dollars, and all payment under this Agreement shall be made in U.S.
dollars. 
 8.4 Late Payments. Fees not paid when due shall accrue late charges at a rate of [...***...] per month, or the
maximum rate allowed under law, whichever is lower, from the date such payment was due until the date paid. 
 8.5 Taxes. All payments
made under this Agreement do not include any taxes, duties or charges of any kind imposed by any federal, state, or local governmental entity. When RFM has the legal obligation to collect and remit such taxes, excluding only taxes based solely on
RFM’s net income, the appropriate amount shall be due upon invoice to ST unless ST provides RFM with a valid tax exemption certificate authorized by the appropriate taxing authority. All payments by ST shall be made free and clear of, and
without reduction for, any withholding taxes. Any such taxes which are otherwise imposed on payments to RFM shall be the sole responsibility of ST. ST shall provide RFM with official receipts issued by the appropriate taxing authority or such other
evidence as is reasonably requested by RFM to establish that such taxes have been paid. 
 8.6 Audit Rights. During the term of this
Agreement and for [...***...] thereafter, ST shall maintain complete and accurate books and records with respect to the sale of Products, or otherwise pertaining to the payment of fees hereunder (“ST Records”). RFM may have an
independent auditor, on at least seven (7) calendar days prior notice to ST, audit the ST Records, provided that such audits shall not be performed more frequently than [...***...] period. Any such audit must be performed during normal
business hours and conducted in such a manner as not to interfere with the ordinary conduct of ST’s business. The auditor conducting such audit must execute an appropriate confidentiality agreement with respect to ST’s non-public and
proprietary information. The audit will be at RFM’s cost and expense, unless, however, such audit reveals an underpayment of [...***...] or more for the period audited, then ST shall immediately pay the shortage (including interest
pursuant to Section 8.4) and the costs and expenses of such audit. The auditors will report to RFM only upon whether the royalties paid to RFM by ST were or were not correct, and if incorrect, what are the correct amounts for the royalties. ST
shall be supplied with a copy of or sufficient extracts from any report prepared by the auditors. 
  

 - 6 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 8.7 Product Pricing. ST must list Products as a separate line item on all ST price lists and
any purchase orders or invoices related to Products. For the avoidance of doubt, RFM acknowledges and agrees that no royalty shall be due to [...***...]. No royalty will accrue for [...***...]. 
  

	 	9.	TERM AND TERMINATION. 

 9.1 Term. This Agreement will commence on the Effective Date and shall continue for a term of three (3) years, unless earlier terminated as set forth Herein. The Agreement shall renew automatically for
additional terms of one (1) year unless either party gives written notice of its intent to terminate at least ninety (90) calendar days prior to the expiration of the then-current term. 
 9.2 Termination for Failure to Invest. If ST fails to purchase three million dollars ($3,000,000) of preferred stock in RFM’s Series C
financing pursuant to mutually agreed upon terms on or before June 2, 2003, RFM may, at its option and election, terminate this Agreement effective upon written notice to ST. 
 9.3 Termination for Cause. Either party may terminate this Agreement upon written notice If (i) the other party materially breeches any term
or condition of this Agreement and fails co cure such breach within thirty (30) calendar days alter receiving written, notice of such breach, or (ii) the other party becomes the subject of any voluntary or involuntary proceeding under the
applicable bankruptcy or insolvency laws and such proceeding is not dismissed within sixty days after the other party’s receipt of written notice of such proceeding. 
 9.4 Effect of Termination or Expiration. 
 (A) Return of Materials. Within thirty
(30) calendar days after the expiration or termination of this Agreement (subject only to any ST right to fulfill purchase orders pursuant to Section 9.4(B), and in such case, upon expiration of such rights), each party will return all
Confidential Information of the other party in its possession or control for shipment or, upon the other party’s request, destroy such information. Within thirty (30) calendar days of a written request by the other party, an officer of
each party shall certify to the other party that all copies of Confidential Information of the other party received hereunder have been returned or destroyed pursuant to this Section 9.4(A). 
 (B) Outstanding Purchase Orders. If ST terminates this Agreement pursuant to Section 9.3, ST shall have [...***...]. If RFM terminates
this Agreement pursuant to Section 9.3, ST may [...***...]. 
 9.5 Survival. Notwithstanding any expiration or termination
of this Agreement, all payment obligations incurred prior to expiration or termination shall survive, and the following provisions shall survive: 1 (Definitions), 2 (Scope of Agreement), 4.3 (ST License Restrictions), 6.2 (Mask Proprietary Rights),
7 (Proprietary Rights), 8 (Royalties and Payment), 9.4 (Effect of Termination), 9.5 (Survival), 10.3 (Disclaimer), 11 (Indemnification), 12 (Confidentiality), 13 (Limitation of Liability) and 14 (Miscellaneous). In addition, if RFM terminates
this Agreement pursuant to Section 9.2, Section 4.1 shall survive solely as necessary for ST to exercise its rights under Section 9.4(B). All other rights and licenses granted hereunder will cause upon expiration or termination.

  

	 	10.	LIMITED WARRANTIES AND DISCLAIMER. 

 10.1 Limited Warranties. Each party represents and warrants to the other party that: (a) it has full power and authority to enter into this
Agreement and to carry out the transactions contemplated by this Agreement, and (b) the execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated by this Agreement, have been duly authorized by
all requisite corporate action on the part of each party; provided, however, that the foregoing shall not be construed as representation or warranty that the exploitation or the use of any RFM Materials does not infringe or misappropriate any third
party rights. As of the Effective Date, RFM warrants to ST that, to its knowledge, the IC Design does not infringe any third party Intellectual Property Rights. During the [...***...] period immediately following the First Commercial
Production Date, RFM warrants to ST that the IC Design shall conform to the Specifications in all material respects. 
  

 - 7 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 10.2 Remedy. If the IC Design does not conform as expressly warranted in the last sentence of
Section 10.1, RFM shall use reasonable efforts to modify such IC Design so that it complies with such warranty and reimburse ST for any actual direct costs incurred by ST in manufacturing replacement Products that conform to such modified IC
Design; provided that, upon RFM’s request, ST provides RFM with reasonable documentation showing such costs. THE FOREGOING PROVISIONS OF THIS SECTION 10.2 STATE THE ENTIRE LIABILITY AND OBLIGATIONS OF RFM, AND THE EXCLUSIVE REMEDY OF ST IF
DURING THE [...***...] PERIOD IMMEDIATELY FOLLOWING THE FIRST COMMERCIAL PRODUCTION DATE THE IC DESIGN DOES NOT CONFORM TO THE SPECIFICATIONS IN ALL MATERIAL RESPECTS. 
 10.3 Disclaimer. EXCEPT FOR THE WARRANTIES GRANTED UNDER SECTION 10.1, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER
ORAL OR WRITTEN, WHETHER EXPRESS, IMPLIED, OR ARISING BY STATUTE, CUSTOM, COURSE OF DEALING OR TRADE USAGE, WITH RESPECT TO THE SUBJECT MATTER HEREOF, IN CONNECTION WITH THIS AGREEMENT. EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED
WARRANTIES OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. 
  

	 	11.	INDEMNIFICATION. 

 11.1 Subject to
Section 11.3 and the terms of this Agreement, RFM shall indemnify and hold ST and ST’s Affiliates, (hereafter referred as “ST Indemnities”) harmless against and shall pay all damages fully awarded by a court of competent
jurisdiction, including reasonable attorneys’ fees, resulting from any suit, complaint, demand, action by a third party against ST Indemnities to the extent such suit, complaint, demand, or action alleges that the RFM Materials infringe the
Intellectual Property Rights of a third party (“ST Infringement Claim”), provided that: (i) ST gives written notice to RFM within ten (10) business days after receipt of written notice of such ST Infringement Claim (provided that
ST’s failure to provide such notice will relieve RFM of its indemnification obligations only if and to the extent that such failure prejudices RFM’s ability to defend the ST Infringement Claim), (ii) ST allows RFM at its expense
through attorneys of its own choice, to exclusively defend and/or control the defense of any ST Infringement Claim, and (iii) upon RFM request, ST shall provide full information, cooperation, and assistance in such investigation and defense,
and is reimbursed by RFM for all the reasonable costs incurred in collaborating in such investigation and defense, including trial and any appeals. ST may also participate, at its option and at its own expense, in such defense. No settlement of a ST
Infringement Claim that involves a remedy other than payment of money by RFM shall be agreed to and entered into without the consent of ST, whose consent shall not be unreasonably withheld or delayed. 
 11.2 Without limiting the indemnification obligation set forth in Section 11.1 above, if it is determined, or if RFM reasonably believes, that the
RFM Materials or any portion thereof infringes any third party intellectual property right, then RFM may, at its option and expense: (i) procure for ST the right to continue using such RFM Materials or portion thereof in accordance with this
Agreement; (ii) replace RFM Materials or portion thereof with a substantially similar non-infringing alternative; or (iii) modify such RFM Materials with at least functionally equivalent modification so that ST’s use becomes
non-infringing. RFM will not be liable for any costs or expenses incurred by ST or for any costs of replacement items, without RFM’s prior written authorization. 
 11.3 RFM shall have no liability under Section 11.1 for any claim of infringement based on (i) modification of the RFM Materials other than by RFM, (ii) use of other than the current version of the RFM
Materials despite the fact that RFM has offered to ST a modification or replacement of the RFM Materials and granted to ST a reasonable period of time to implement such new version of the RFM Materials in the applicable Products, (iii) the
combination or use of the RFM Materials furnished hereunder with materials not furnished or authorized in writing by RFM if such infringement would have been avoided by use of the Indemnified Materials alone, or (iv) the use of the RFM
Materials in violation of the licenses granted by RFM in Section 4.1 above. 
  

 - 8 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 11.4 Subject to Section 11.5 and the terms of this Agreement, ST shall indemnify and hold RFM
harmless against and shall pay all damages finally awarded by a court of competent jurisdiction, including reasonable attorneys’ fees, to the extent resulting from: (A) act that would be excluded from RFM’s indemnity obligations
pursuant to subsections (i), (ii), (iii) and/or (iv) of Section 11.3 above, or (B) any suit, complaint. demand, action by a third party against RFM alleging that the ST Deliverables infringe the Intellectual Property Rights of a
third party, provided that: (i) RFM gives written notice to ST within ten (10) business days after receipt of written notice of a claim (provided that RFM’s failure to provide such notice will relieve ST of its indemnification
obligations only if and to the extent that such failure prejudices ST’s ability to defend the claim); (ii) RFM allows ST at its expense through attorneys of its own choice, to exclusively defend and/or control the defense of the claim; and
RFM shall provide full information. cooperation, and assistance in such investigation and defense, and is reimbursed by ST for all the reasonable costs incurred in collaborating in such investigation and defense, including trial and any appeals,
provided that such RFM may also participate, at its option and at its own expense, in such defense. 
 11.5 ST shall have no liability under
Section 11.4 for any claim of infringement based on (i) modification of ST Deliverables other than by ST; (ii) use of other than the current version of the ST Deliverables despite the fact that ST has offered to RFM a modification or
replacement of the ST Deliverables and granted to RFM a reasonable period of time to implement use of such ST Deliverables pi scant to this Agreement, (iii) the combination or use of the ST Deliverables with or other materials if such
infringement would have been avoided by use of the ST Deliverables alone, or (iv) the use of the ST Deliverables in violation of the license granted by ST in Section 4.4 above. 
 11.6 Exclusive Remedy. THE FOREGOING PROVISIONS OF THIS ARTICLE 11 STATE THE ENTIRE LIABILITY AND OBLIGATIONS OF EACH PARTY, AND THE SOLE AND
EXCLUSIVE REMEDY OF THE OTHER PARTY, WITH RESPECT TO ANY ACTUAL OR ALLEGED INFRINGEMENT OF ANY PATENT, COPYRIGHT, MASK WORK RIGHT, TRADEMARK, TRADE SECRET OR OTHER INTELLECTUAL PROPERTY RIGHT OR BREACH OF ANY INTELLECTUAL PROPERTY NON-INFRINGEMENT
WARRANTY. 
  

	 	12.	CONFIDENTIALITY. 

 12.1
Definition. As used in this Agreement, the term “Confidential Information” means (a) any information disclosed by one party to the other pursuant to this Agreement which is in written, graphic, machine readable or other
tangible form and is marked “Confidential”, “Proprietary” or in some other manner to indicate its confidential nature, (b) oral information disclosed by one party to the other pursuant to this Agreement, provided that such
information is designated as confidential at the time of disclosure and reduced to a written summary by the disclosing parry, within thirty (30) calendar days after its oral disclosure, which is marked in a manner to indicate its confidential
nature and delivered to the receiving party, and (c) information otherwise reasonably expected to be treated in a confidential manner under the circumstances of disclosure. Notwithstanding the foregoing, all pricing terms in this Agreement and
RFM Materials shall be deemed Confidential Information of RFM. 
 12.2 Obligations. Neither party shall use any Confidential
Information of the other party for any purpose except as expressly set forth in this Agreement or otherwise authorized in writing in advance by the other party. Neither party shall disclose any Confidential Information of the other party to third
parties or to such party’s employees, except to those employees of the receiving party who are required to have the information in order for the receiving party to perform its obligations under this Agreement. Each party agrees, that it shall
take reasonable measures to protect the secrecy of and avoid disclosure and unauthorized use of the Confidential Information of the other party. Without limiting the foregoing, each party shall take at least those measures that it takes to protect
its own confidential information of a similar nature and shall ensure that its employees and contractors who have access to Confidential Information of the other party have signed a non-use and non-disclosure agreement in content at least as
protective of the other party’s Confidential Information as the provisions hereof prior to any disclosure of Confidential Information to such employees or contractors. Each party may disclose the existence of this Agreement, but agrees that the
terms and conditions of this Agreement will be treated as Confidential Information of the other party. 
  

 - 9 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 12.3 Exceptions. Notwithstanding the above, neither party shall have any obligations under
this Article 12 with regard to any Confidential Information of the other party which: (a) was generally known and available in the public domain at the time it was disclosed or becomes generally known and available in the public domain
through no fault of the receiving party; (b) can be documented as previously known by the receiving party prior to disclosure thereof by the disclosing party; (c) is disclosed with the prior written approval of the disclosing party;
(d) was independently developed by the receiving party without any use of the disclosing party’s Confidential Information; or (e) becomes known to the receiving party from a source other than the disclosing party without breach of
this Agreement by the receiving party and otherwise not in violation of the disclosing party’s rights. Nothing in this Agreement shall prevent the receiving party from disclosing Confidential Information to the extent the receiving party is
legally compelled to do so by any governmental investigative or judicial agency pursuant to proceedings over which such agency has jurisdiction; provided, however, that prior to any such disclosure, the receiving party shall: (x) assert the
confidential nature of the Confidential Information to such agency; (y) immediately notify the disclosing party in writing of such agency’s order or request to disclose; and (z) cooperate fully with the disclosing party in protecting
against any such disclosure and/or obtaining a protective order narrowing the scope of the compelled disclosure and protecting its confidentiality. 
 12.4 Authorized Disclosure. Notwithstanding the provisions of this Article 12, each party may disclose the terms of this Agreement (a) in connection with the requirements of an initial public offering or securities filing;
(b) in confidence, to accountants, banks, and financing sources and their advisors; (c) in confidence, in connection with the enforcement of this Agreement or rights under this Agreement; or (d) in confidence, in connection with a
merger or acquisition or proposed merger or acquisition, or the like. 
 12.5 Remedies. Each party agrees that any violation or
threatened violation of this Agreement may cause irreparable injury to the other party, entitling the other party to seek injunctive relief in addition to all legal remedies. 
 13. LIMITATION OF LIABILITY. EXCEPT FOR ANY BREACH OF SECTION 4.3 OR 12, AND EXCEPT FOR ANY
INDEMNIFICATION OBLIGATIONS UNDER SECTION 11, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING BUT NOT LIMITED TO DAMAGES FOR LOST DATA, LOST
PROFITS, DOWNTIME OR COSTS OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, HOWEVER CAUSED AND ARISING UNDER ANY THEORY OF LIABILITY, INCLUDING BUT NOT LIMITED TO CONTRACT OR TORT (INCLUDING PRODUCTS LIABILITY, STRICT LIABILITY AND NEGLIGENCE), AND
WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 EXCEPT FOR ANY BREACH OF SECTION 4.3 OR 12, IN NO EVENT SHALL ST’S
CUMULATIVE LIABILITY ARISING OUT OF THIS AGREEMENT EXCEED [...***...]. 
 EXCEPT FOR ANY BREACH OF SECTION 4.3 OR 12, IN NO EVENT SHALL RFM’S
CUMULATIVE LIABILITY ARISING OUT OF THIS AGREEMENT EXCEED [...***...]. 
 THE FOREGOING LIMITATIONS IN THIS ARTICLE 13 SHALL APPLY NOTWITHSTANDING THE
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY STATED IN THIS AGREEMENT. 
  

	 	14.	MISCELLANEOUS. 

 14.1 Inherently
Dangerous Applications. The IC Design and IC Design File are not designed or authorized for use in the manufacture of Products for use in life support appliances, devices, or systems where malfunction of a Product can reasonably be expected to
result in a personal injury or for use in aviation, nuclear or any other inherently dangerous application. ST and its customers using or selling Products for use in such applications do so at their own risk. 
  

 - 10 - 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 14.2 Joint Press Release. Subject to Section 12, neither party shall make any
announcement or press release regarding this Agreement or any terms thereof without the other Party’s prior written consent. 
 14.3
Assignment. Neither party may assign or otherwise transfer this Agreement or any rights under this Agreement, in whole or in part, whether voluntarily or by operation of law without the other party’s prior written consent.
Notwithstanding the foregoing, REM shall have the right to assign, whether voluntarily or by operation of law, without prior written consent in the event of a transfer of all or substantially all of RFM’s business or assets whether by asset
acquisition, merger, consolidation or otherwise (“Acquisition”). Notwithstanding any other provision in this Agreement, in the event RPM assigns this Agreement in connection with an Acquisition to a third party
(“Acquirer”): [...***...]. Subject to the foregoing, this Agreement will be binding upon and will inure to the benefit of the parties and their respective successors and assigns. Any assignment in violation of this
Section 14.3 will be null and void. 
 In the event of an Acquisition by an Acquirer that is a [...***...] company that has a closing date before
[...***...], ST would have the option to terminate this Agreement upon written notice to RFM within [...***...]; provided that any such termination would only take effect [...***...] (“Option”). If ST exercises the
Option, Section 5.1 would terminate; provided, however, that during the Exclusive Period, ST would not, without RFM’s prior written consent, sell or otherwise distribute, whether directly or indirectly, any products that in the
parties’ reasonable judgment compete with the Products. 
 14.4 Governing Law. This Agreement shall be governed, construed and
enforced in accordance with the laws of the State of New York and the United States of America, without reference to conflict of laws principles and without regard to the United Nations Convention on Contracts for the International Sales of Goods.

 14.5 Dispute. The parties shall attempt in good faith to resolve any dispute or claim arising out of or in connection with this
Agreement or the performance, breach or termination thereof (“Dispute”). Any Dispute not resolved by mutual agreement pursuant to the foregoing sentence within a period of sixty (60) days after the date of delivery of first written
notice of the Dispute from one party to the other party describing the Dispute in reasonable detail will be submitted by the parties to binding arbitration before an arbitral tribunal consisting of three arbitrators appointed in accordance with the
Rules of Arbitration of the International Chamber of Commerce (ICC). The arbitration tribunal, including all staff, all witnesses, and any permitted attending non-parties, shall be legally bound by agreements and/or orders to prevent disclosure of
any information which may be disclosed to them in connection with arbitration proceedings conducted under this Section 14.5. The arbitration shall take place in the city of New York, New York, United States of America in the English language
and according to the Rules of Arbitration of the ICC. The arbitrators shall apply the laws of the State of New York and the United States of America, without reference to conflict of laws principles, to the merits of the dispute and in all cases
shall decide in accordance with the terms of this Agreement. The arbitral decision and award shall be final and binding. The arbitral decision and award shall be final and binding and shall deal with the questions of costs of arbitration an all
matters related thereto. Any costs, fees or taxes involved in enforcing the award shall be fully assessed against and paid by the party resisting enforcement of the award. Notwithstanding the foregoing, either party may apply to any court of
competent jurisdiction for injunctive relief without breach of this arbitration provision. Judgment on the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. 
 14.6 Subcontractor. RFM has the right to use third party contractors to exercise its rights and fulfill its obligations under this Agreement.

 14.7 Independent Contractors. The relationship of the parties under this Agreement is that of independent contractors. Neither
party will be deemed to be an employee, agent, partner, franchisor, franchisee or legal representative of the other for any purpose and neither will have any right, power or authority to create any 

  

					
		 	- 11 -	 	

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 
obligation or responsibility on behalf of the other. ST shall not purport to take on any obligation or responsibility, or make any representations,
warranties, guarantees or endorsements to anyone, on behalf of RFM including, without limitation, relating to Products. 
 14.8
Severability and Headings. If any term, condition or provision of this Agreement is held to be invalid, unlawful or unenforceable to any extent by a court of competent jurisdiction, then the parties agree to negotiate in good faith a
substitute, valid and enforceable provision that most nearly effects the parties’ intent and to be bound by mutually agreed substitute provision. If the parties fail to agree on such an amendment, such invalid term, condition or provision will
be severed from the remaining terms, conditions and provisions, which will continue to be valid and enforceable to the fullest extent permitted by law. Headings used in this Agreement are provided for convenience only, and shall not in any way
affect the meaning or interpretation of this Agreement. 
 14.9 Negotiated Terms. The parties agree that the terms and conditions of
this Agreement are the result of negotiations between the parties and that this Agreement shall not be construed in favor of or against any party by reason of the extent to which any party or its professional advisors participated in the preparation
of this Agreement. 
 14.10 No Waiver. Any waiver of the provisions of this Agreement or of a party’s rights or remedies under
this Agreement must be in writing to be effective. Failure, neglect or delay by a party to enforce the provisions of this Agreement or its rights or remedies at any time, will not be construed as a waiver of such party’s rights under this
Agreement and will not in any way affect the validity of the whole or any part of this Agreement or prejudice such party’s right to take subsequent action. No exercise or enforcement by either party of any right or remedy under this Agreement
will preclude the enforcement by such party of any other right or remedy under this Agreement or that such party is entitled by law to enforce. 
 14.11 Force Majeure. Neither party will be liable to the other party on account of any loss or damage resulting from any delay or failure to perform all or any part of this Agreement if such delay or failure is caused, in whole or in
part, by events, occurrences, or causes beyond the control and without negligence of the parties (“Force Majeure Event”). Such events, occurrences, or causes will include, without limitation, acts of God, strikes, lockouts, riots, acts of
war, earthquake, fire and explosions, but the inability to meet financial obligations is expressly excluded. The party affected by Force Majeure Event shall inform promptly the other party in writing of the Force Majeure Event’s occurrence,
anticipated duration and cessation. 
 14.12 Language. This Agreement is in the English language only, which language shall be
controlling in all respects, and all versions hereof in any other language shall not be binding on the parties hereto. All communications and notices to be made or given pursuant to this Agreement shall be in the English language. 
 14.13 U.S. Export Control. ST understands and acknowledges that RPM is subject to regulation by agencies of the U.S. Government, including, but
not limited to, the U.S. Department of Commerce, which prohibit export or diversion of certain products and technology to certain countries. Any and all obligations of RFM to provide RFM Materials or any media in which any of the foregoing is
contained, as well as any other technical information and assistance shall be subject in all respects to such United States laws and regulations as shall from time to time govern the license and delivery of technology and products abroad by persons
subject to the jurisdiction of the United States, including the Export Administration Act of 1979, as amended, any successor legislation, and the Export Administration Regulations issued by the Department of Commerce, Bureau of Export
Administration. ST agrees to cooperate with RFM, including, without limitation, providing required documentation, in order to obtain export licenses or exemptions therefrom. ST warrants that it will comply with the Export Administration Regulations
and other United States laws and regulations governing exports in effect from time to time. 
 14.14 Compliance with Laws. ST shall at
all times conduct its efforts hereunder in strict accordance with all applicable laws, rules, policies, directives and regulations. 

					
		 	- 12 -	 	

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 14.15 Notices. Any notice required or permitted under the terms of this Agreement or required
by law must be in writing and must be: (a) delivered in person, (b) sent by first class registered mail, or air mail, as appropriate, or (c) sent by overnight air courier, in each case properly posted and fully prepaid to the
appropriate address set forth below. Either party may change its address for notice by notice to the other party given in accordance with this Section. Notices will be considered to have been given at the time of actual delivery in person, seven
(7) calendar days after deposit in the mail as set forth above, or two (2) calendar days after delivery to an overnight air courier service. 
  

			
	STMicroeletronics N.V.	  	RF Magic Inc.
	39, Chemin du Champ des Filles	  	10182 Telesis Court, 4th Floor
	1228 Plan-les-Ouates	  	San Diego, California 92121-4777
	Geneva, Switzerland	  	Attention:                                     
   
	Attention: General Counsel	  	
		
	With a copy to:	  	With a copy to
		
	STMicroelectronics, Inc.	  	RF Magic Inc.
	1310 Electronics Drive, MS 2346	  	10182 Telesis Court, 4th Floor
	Carrollton, Texas 75006	  	San Diego, California 92121-4777
	Attention: General Counsel	  	Attention:                                     
   

 14.16 Entire Agreement. This Agreement (including the Exhibits, Appendices, and any addenda
hereto signed by both parties) contains the entire agreement of the parties with respect to the subject matter of this Agreement and supersedes all previous communications, representations understandings and agreements, either oral or written,
between the parties with respect to said subject matter. No terms, provisions or conditions of any purchase order, acknowledgment or other business form that either party may use in connection with the transactions contemplated by this Agreement
will have any effect on the rights, duties or obligations of the parties under, or otherwise modify, this Agreement, regardless of any failure of a receiving party to object to such terms, provisions or conditions. This Agreement may not be amended,
except by a writing signed by both parties. 
 14.17 Execution in Counterparts. This Agreement and any Exhibits hereto may be executed
in counterparts, each of which will be deemed an original and all of which together will constitute one instrument. 
 IN WITNESS WHEREOF,
the parties by their duly authorized representatives have executed this Agreement as of the Effective Date. 
  

					
	RF Magic, Inc.	 		 	STMicroelectronics N.V.
			
	 /s/ Mark H. Foley
	 		 	 /s/ Mr. Geyees

	Signature	 		 	Signature
			
	 Mark H. Foley
	 		 	 Mr. Geyees

	Printed Name	 		 	Printed Name
			
	 CEO and President
	 		 	 Corporate Vice President

	Title	 		 	Title
			
	  
	 		 	 June 2, 2003

	Date	 		 	Date

					
		 	- 13 -	 	

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 EXHIBIT A 
 DEVELOPMENT PLAN 
 [None] 
  

					
		 	1	 	

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 EXHIBIT B 
 DEVELOPMENT SCHEDULE 
 [None] 
  

					
		 	1	 	

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 EXHIBIT C 
 SPECIFICATIONS 
 [...***...] 

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 EXHIBIT D 
 EXISTING RF PRODUCT, ROYALTIES AND EXCLUSIVE PERIOD 
 ST EXISTING RF
PRODUCT: “ST Existing RF Product” means [...***...]. 
 ROYALTIES: 
 For each Product sold by ST to a third party, ST shall pay RFM the Royalties for such Product. 
 “Royalties” means, with respect to each Product shipped or otherwise delivered by ST to a third party, the greater of (i) [...***...], or (ii) [...***...] for such Product.

 “Minimum Royalty” means, with respect to each Product, the minimum royalty amount to be paid by ST to RFM, as mutually agreed upon in
writing by the parties. Prior to the first shipment of Product by ST to a Customer, the parties shall negotiate in good faith and agree in writing upon the Minimum Royalty. Thereafter, the parties shall negotiate in good faith and agree in writing
upon a revised Minimum Royalty prior to, and effective on, [...***...]. In the event the parties do not agree on a revised Minimum Royalty prior to [...***...] pursuant to the foregoing sentence, [...***...]. 
 “Gross Margin” means, with respect to each Product, Gross Sales minus Product Price. 
 “Product Cost” means, the calendar year price set forth in the table below [...***...]. 
  

			
	2003	  	[...***...]
	2004	  	An amount to be mutually agreed upon by the parties in writing at least [...***...], but in no event no less than [...***...]. In the event the parties do not agree on an amount
pursuant to the preceding sentence, then RFM may, at its option, [...***...] upon written notice to ST.
	2005 and thereafter	  	With respect to each applicable calendar year, an amount to be mutually agreed upon by the parties in writing at least [...***...], but in no event to exceed [...***...]. In the
event the parties do not agree on an amount pursuant to the preceding sentence, then RFM may, at its option: (i) [...***...], or (ii) [...***...].

 “Gross Sales” means, with respect to each Product, the total amount invoiced to third parties for
such Product by ST or its Affiliates. 
 ST and its Affiliates shall use reasonable efforts to maximize Gross Sales for the Products. In the event that ST or
its Affiliates sell Products to a third party who also purchases other products or services from ST or its Affiliates, ST shall not, and shall require its Affiliates not to, [...***...]. Without limiting the foregoing, ST shall not, and shall
require its Affiliates not to, treat Products in such a manner that would [...***...]. 
 During the Exclusive Period, if ST in good faith believes,
with respect to a particular sale of Products to a Customer, that: (i) [...***...]; and (ii) [...***...], then ST shall be entitled to request that RFM reduce the effective Minimum Royalty on such Products to ST for such
Customer. [...***...]. 
  

					
		 	1	 	***Confidential Treatment Requested

 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 
 Confidential Treatment Requested

 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 
  

 EXCLUSIVE PERIOD: 
 “Exclusive Period” means, collectively, the Initial Restriction Period and any Additional Restriction Period. 
 “Initial Restriction Period” means [...***...]. 
 “Additional Restriction Period” means the [...***...] period immediately following the expiration of the Initial Restriction Period; provided, however, that ST sells and ships to a third party (other than an
Affiliate) at least [...***...] units of Products during each [...***...] period commencing on [...***...] and thereafter upon each [...***...] until expiration of such [...***...]. For the purposes of clarification, if
ST does not ship and sell at least [...***...] units of Product in any such [...***...]. 
 Notwithstanding any other provision in his Agreement,
the Exclusive Period shall immediately and automatically terminate in the event (i) the relationship of the parties under this Agreement for ST and the Affiliates to manufacture and sell the Products is [...***...], and
(ii) [...***...]. 
  

					
		 	2	 	***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]